UK - Oxford Capital Partners backs Glide Pharma with £2.3m

Oxford Capital Partners has joined existing investors on a £2.3m funding round for Glide PharmaTM, the specialty pharmaceutical company developing products based on its innovative needle-free Glide SDI™ drug delivery system. Existing shareholders include Oxford Technology 4 VCT, which led a £2.1m investment in the company in early 2006. Under a separate agreement, Glide Pharma has also entered into an exclusive licence and distribution deal with Paladin Labs Inc, a leading Canadian specialty pharmaceutical company, for Glide Pharma products in Canada.